TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24193291
Drug: Irsogladine maleate
Normalized name: maleate
DrugBank: Irsogladine (DB13056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irsogladine maleate (IM) 4 mg/body/day for two years
Study: 24193291
Drug: Uracil-tegafur (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uracil-tegafur (250 mg/m2/day) for two years (Control)
Study: 21367595
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg daily for 12 months
Study: 16534529
Drug: Individualised Dietetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised Dietetic Treatment (IDT)
Study: 12927929
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily interferon (IFN)-beta (3 MU bid)
Study: 12927929
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily interferon (IFN)-beta (6 MU qd)
Study: 9326983
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium nitroprusside
Study: 3358882
Drug: Intravenous nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nifedipine
Study: 3512747
Drug: Naproxen 5
Normalized name: naproxen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 5 mg/kg twice daily for eight weeks
Study: 27829454
Drug: 26-week dose
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 26-week dose reduction group (N = 120)
Study: 27829454
Drug: No-dose-reduction group
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-dose-reduction group (N = 129)
Study: 22086491
Drug: Progressive home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive home-based strengthening exercise program (PHSEP) for 8 weeks in addition to weekly institutional exercise therapy
Study: 22086491
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continued weekly institutional exercise sessions
Study: 20737957
Drug: Systemic medical
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic medical treatment
Study: 12393528
Drug: Iron chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron chelation treatment
Study: 8791954
Drug: Amoxycillin 750
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 750 mg b.d. + omeprazole 40 mg b.d.
Study: 8791954
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.d. + placebo
Study: 12854150
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no specific treatment)
Study: 3063044
Drug: Thiopentone 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 4.0 mg/kg i.v.
Study: 30170904
Drug: Ambulatory oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory oxygen treatment for 2 weeks
Study: 30170904
Drug: No oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oxygen treatment for 2 weeks
Study: 27075216
Drug: Proactive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive treatment group (intermittent preventive application of topical corticosteroid for 1 year)
Study: 27075216
Drug: Proactive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive treatment group
Study: 21855126
Drug: Nocturnal asthma
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal asthma symptoms requiring albuterol (NASRAs)
Study: 21855126
Drug: Nocturnal asthma
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal asthma symptoms requiring albuterol (NASRAs) during exacerbation periods
Study: 2234804
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone drops
Study: 355604
Drug: BCNU (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU (80 mg/sq m/day on 3 successive days every 6 to 8 weeks)
Study: 31814226
Drug: Malic acid
Normalized name: Malic Acid
DrugBank: Malic acid (DB12751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malic acid lozenge
Study: 22446490
Drug: Bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150 mg)
Study: 23052417
Drug: Bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (300 mg)
Study: 10828671
Drug: Propiverine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine (15 mg t.i.d.)
Study: 10784360
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II pressor dose (1-3 microg/min)
Study: 10784360
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II subpressor dose (0.0375-0.15 microg/min)
Study: 10784360
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II pressor dose + Losartan (50 mg)
Study: 10784360
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II subpressor dose + Losartan (50 mg)
Study: 10583037
Drug: Placebo (electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (electrolyte solution)
Study: 1833529
Drug: Meperidine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (12.5 mg every 5 minutes up to a maximum of 50 mg)
Study: 8636581
Drug: Cardiovascular medications
Normalized name: CARDIOVASCULAR MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiovascular medications
Study: 28956671
Drug: Raw crushed
Normalized name: raw sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw crushed garlic (100 mg/kg body weight, 2 times a day for 4 weeks)
Study: 26615605
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg/day plus standard ADHF therapy
Study: 26615605
Drug: Standard ADHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ADHF therapy alone
Study: 17095117
Drug: Fluid Replacement
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid Replacement Trial (FR-trial) - water bolus (5.0 mL/kg body mass) ingested immediately pre-exercise and every 20 min during exercise (2.0 mL/kg body mass)
Study: 10634370
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg/day)
Study: 10661828
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg/day)
Study: 10199771
Drug: Ketoconazole (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (300 mg/day)
Study: 2242455
Drug: Surgeons who
Normalized name: sturgeon, unspecified preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgeons who offered a choice of treatment
Study: 22180577
Drug: Combination pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pharmacotherapy (bupropion, nicotine lozenge, nicotine patch, bupropion + lozenge, patch + lozenge)
Study: 17934827
Drug: Concurrent immunomodulators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent immunomodulators
Study: 15901041
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride 100 mg tablets (formulation 1)
Study: 15901041
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride 100 mg tablets (formulation 2)
Study: 8750405
Drug: Bisoprolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (2.5 to 10 mg/d)
Study: 2027477
Drug: Phosphatidylserine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine (100 mg BC‐PS tid)
Study: 6487752
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release capsule (15 mg)
Study: 29037240
Drug: KH176 single
Normalized name: KH176
DrugBank: Sonlicromanol (DB16333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KH176 single dose of 800 mg
Study: 29037240
Drug: KH176 multiple
Normalized name: KH176
DrugBank: Sonlicromanol (DB16333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KH176 multiple doses of 400 mg b.i.d. for 7 days
Study: 29037240
Drug: KH176 single
Normalized name: KH176
DrugBank: Sonlicromanol (DB16333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KH176 single doses of 2000 mg
Study: 29037240
Drug: KH176 pharmacokinetics
Normalized name: KH176
DrugBank: Sonlicromanol (DB16333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KH176 pharmacokinetics
Study: 29037240
Drug: KH176 renal
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: KH176 renal excretion
Study: 15166533
Drug: Attention-control clinics
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-control clinics (medication adherence)
Study: 26871700
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (BVB) 1.25 mg
Study: 28098951
Drug: Web‐based feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web‐based feedback on hazardous drug exposures plus tailored messages to address barriers
Study: 26143313
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine 2 mg
Study: 10376116
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (250 mg orally twice daily for 4 months)
Study: 29549067
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) for 14 weeks
Study: 15089890
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg b.i.d.
Study: 1606995
Drug: Alprazolam 1
Normalized name: alprazolam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1 mg alone
Study: 1606995
Drug: Alprazolam 1
Normalized name: alprazolam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1 mg combined with alcohol 0.5 g/kg
Study: 1606995
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule and alcohol 0.5 g/kg
Study: 1606995
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule and placebo drink
Study: 4020207
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg tablet once every fortnight)
Study: 9322328
Drug: Chiropractic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic treatment
Study: 18394446
Drug: Unopposed micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed micronized 17beta‐estradiol 1 mg/day
Study: 28679502
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg every 4 hours)
Study: 22459616
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg LGD-4033
Study: 17707751
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg before the intervention, and 200 mg twice daily for 6 months after the procedure)
Study: 17707751
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard care with aspirin and clopidogrel)
Study: 11524058
Drug: rosuvastatin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 2.5 mg
Study: 15063607
Drug: rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 5 mg
Study: 26539650
Drug: rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 40 mg
Study: 12505568
Drug: rosuvastatin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 80 mg
Study: 26539650
Drug: rosuvastatin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (all doses)
Study: 9284718
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg qd p.o. for four consecutive days starting two days before immunization)
Study: 8313933
Drug: Deflazacort 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort 60 mg/day
Study: 8313933
Drug: Deflazacort 30
Normalized name: deflazacort 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort 30 mg/day
Study: 11679441
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline infusion
Study: 12135033
Drug: Tapering course
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering course of vancomycin
Study: 12135033
Drug: Pulsed dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dosing of vancomycin
Study: 12135033
Drug: High-dose vancomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vancomycin (> or =2 g/day)
Study: 12135033
Drug: Low-dose metronidazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose metronidazole (< or =1 g/day)
Study: 2679473
Drug: Hourly doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly doses of clonidine hydrochloride followed by maintenance therapy (group 1)
Study: 2679473
Drug: An initial
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial dose of clonidine followed by hourly placebo and subsequent maintenance therapy (group 2)
Study: 2679473
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy without prior loading (group 3)
Study: 28642008
Drug: Twice-daily concurrent
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily concurrent chemoradiotherapy (45 Gy in 30 fractions of 1.5 Gy over 19 days)
Study: 28642008
Drug: Twice-daily concurrent
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily concurrent chemoradiotherapy
Study: 25934525
Drug: Sitagliptin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (25 mg titrated up to 50 mg)
Study: 25934525
Drug: Glimepiride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (0.5 mg titrated up to 1 mg)
Study: 15486607
Drug: Sertraline or
Normalized name: sertraline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline or Fluoxetine
Study: 22446490
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg)
Study: 8371822
Drug: Ranitidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (2 dd 150 mg) for 2 weeks
Study: 31292181
Drug: Disease activity‐guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease activity‐guided tapering of biological disease-modifying antirheumatic drugs (bDMARDs)
Study: 17234041
Drug: Psychosocial interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychosocial interventions with psychopharmacology as an adjunct
Study: 17234041
Drug: Psychotropic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medication with psychosocial methods as an occasional adjunct
Study: 14760258
Drug: Live quadrivalent
Normalized name: influenza virus vaccine, live quadrivalent nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live quadrivalent rotavirus vaccine (QRV)
Study: 31567887
Drug: Split-dose PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose PEG (4000 mL/1.73 m PEG solution, half the dose day before and half on the day of colonoscopy)
Study: 31567887
Drug: Single-dose PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose PEG (4000 mL/1.73 m PEG solution day before colonoscopy)
Study: 26216729
Drug: Cytotoxic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic therapy plus placebo
Study: 20961574
Drug: Enuresis alarm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enuresis alarm (as second line treatment)
Study: 20961574
Drug: Desmopressin (as
Normalized name: Desmopressin (as desmopressin acetate) 25 microgram oral lyophilisate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (as second line treatment)
Study: 28917383
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ixekizumab every 2 weeks for weeks 0-12, then every 4 weeks during LTE
Study: 17942835
Drug: Regular stimulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular stimulant use
Study: 15801581
Drug: Interest in
Normalized name: CATH,INTERMIT,14FR MENTOR #3814
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interest in nicotine replacement therapy (NRT)
Study: 11764874
Drug: TCP-coated AML
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCP-coated AML femoral implant
Study: 11764874
Drug: Standard AML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard AML femoral implant (control group)
Study: 3318089
Drug: BCG or
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG or ADR (in cases of treatment failure)
Study: 20973324
Drug: Ice applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice applied 5 minutes before injection
Study: 20973324
Drug: Ice applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice applied 5 minutes after injection
Study: 16187176
Drug: Therapy (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy (standard treatment for HCV)
Study: 12537187
Drug: Retrograde autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrograde autologous priming (RAP) (395 +/- 150 mL)
Study: 10768524
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for aphasia
Study: 1500630
Drug: Peanut immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut immunotherapy
Study: 31881986
Drug: Fortified bread
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified bread with 500 IU/100 g
Study: 31881986
Drug: Fortified bread
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified bread with 1000 IU/100 g
Study: 26764332
Drug: Aged Garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged Garlic Extract (AGE) 2.56 g/d for 90 days
Study: 16237776
Drug: Perioperative parenteral
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative parenteral nutrition
Study: 16237776
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no parenteral nutrition)
Study: 12401582
Drug: 1.5 micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 micro g/kg IV fentanyl
Study: 12401582
Drug: 1.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lidocaine plus 0.35 mg/kg IV propofol
Study: 6809796
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy in an individual format
Study: 26814246
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (0.375% ropivacaine, perineural additives)
Study: 26814246
Drug: Medium Dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Dose (0.2% ropivacaine, perineural additives)
Study: 26814246
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (0.1% ropivacaine, perineural additives)
Study: 26814246
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose
Study: 19057896
Drug: 25% nitrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% nitrous oxide inhalation
Study: 16860171
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d for 20 days (group C, n=14)
Study: 1352246
Drug: ipsapirone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone 10 mg
Study: 8840346
Drug: ipsapirone 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipsapirone 20 mg
Study: 6547988
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg cimetidine daily
Study: 6547988
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pirenzepine daily
Study: 6547988
Drug: Control (pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pre-treatment levels)
Study: 30930051
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training performed twice a week for 10 weeks
Study: 18434976
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (200 microg once daily)
Study: 21905959
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray
Study: 13678869
Drug: Candesartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (target dose 32 mg once daily)
Study: 6221388
Drug: Cefoperazone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone (16 micrograms/ml)
Study: 6221388
Drug: Cefamandole (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (16 micrograms/ml) and/or Tobramycin (4 micrograms/ml)
Study: 31277180
Drug: M-DEPTH (evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-DEPTH (evidence-based stepped care treatment model)
Study: 29216730
Drug: Therapy aimed
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy aimed at cervical muscles only
Study: 29216730
Drug: Complex rehabilitation
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex rehabilitation (combination of relaxing and stretching exercises of cervical muscles with standard therapy for masticatory muscles)